References
Nissen SE, Wolski K, Topol EJ. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 2005; 294 (20): 2581–6
Kendall DM, Rubin CJ, Mohideen P, et al. Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a double-blind, randomized, pioglitazone-comparative study. Diabetes Care 2006; 29: 1016–23
Nissen SE. Adverse events related to muraglitazar use in diabetes: reply. JAMA 2006; 295 (17): 1998
Rights and permissions
About this article
Cite this article
Mayday for Dual PPAR Agonists. Pharmaceutical & Diagnostic Innovation 4, 7–10 (2006). https://doi.org/10.1007/BF03257079
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03257079